

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Carton box**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Synulox Lactating Cow Intramammary suspension

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each syringe contains:Amoxicillin (as amoxicillin trihydrate)	200 mg
Clavulanic acid (as potassium clavulanate)	50 mg
Prednisolone	10 mg

**3. PACKAGE SIZE**

3 syringes  
12 syringes  
24 syringes  
300 syringes

**4. TARGET SPECIES**

Cattle (lactating cows).

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Intramammary use.

**7. WITHDRAWAL PERIODS**

Withdrawal period:  
Meat and offal: 7 days.  
Milk: 84 hours, i.e. 7 milking times with 2 times a day milking or 11 milking times with 3 times a day milking.

**8. EXPIRY DATE**

Exp. {mm/yyyy}

**9. SPECIAL STORAGE PRECAUTIONS**

Do not store above 25 °C.  
Store in a dry place.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Zoetis Belgium S.A.  
2nd Floor, Building 10  
Cherrywood Business Park  
Loughlinstown  
Dublin 18  
D18 T3Y1  
Ireland

**14. MARKETING AUTHORISATION NUMBERS**

Vm 60021/3038

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Polyethylene syringe**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Synulox Lactating Cow

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

Each syringe contains:  
Amoxicillin 200 mg  
Clavulanic acid 50 mg  
Prednisolone 10 mg

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

## **B. PACKAGE LEAFLET**

## **PACKAGE LEAFLET**

### **1. Name of the veterinary medicinal product**

Synulox Lactating Cow Intramammary suspension

### **2. Composition**

Each 3 g intramammary syringe contains:

#### **Active ingredients:**

Amoxicillin (as amoxicillin trihydrate):	200 mg
Clavulanic acid (as potassium clavulanate):	50 mg
Prednisolone:	10 mg

Pale cream/buff coloured oily intramammary suspension.

### **3. Target species**

Cattle (lactating cows)

### **4. Indications for use**

For use in clinical cases of mastitis including cases associated with infections with the following pathogens:

Staphylococci (including  $\beta$ -lactamase producing strains)

Streptococci (including *S.agalactiae*, *S.dysgalactiae* and *S.uberis*)

*Escherichia coli* (including  $\beta$ -lactamase producing strains)

### **5. Contraindications**

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in animals which are known to be hypersensitive to  $\beta$ -lactamase antibiotics.

### **6. Special warnings**

#### Special warnings:

Do not use in cases associated with *Pseudomonas*.

#### Special precautions for safe use in the target species:

Swab teat end with appropriate disinfectant before treatment.

### **Recommendations for prudent use**

The product should be used for treatment of clinical mastitis only.

Use of the product should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria and take into account official and local antimicrobial policies.

The use of the product should preferably be based on susceptibility tests.

Avoid use of the product in herds where no  $\beta$ -lactamase producing *Staphylococci* strains have been isolated. *Veterinarians should strive to use narrow spectrum antibiotics if possible.*

Inappropriate use of the product may increase the prevalence of bacteria resistant to  $\beta$ -lactam antibiotics and may decrease the effectiveness of treatment with  $\beta$ -lactam antibiotics, due to the potential for cross-resistance.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.

Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations.

Handle this product with great care to avoid exposure, taking all recommended precautions.

If you develop symptoms following exposure such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty with breathing, are more serious symptoms and require urgent medical attention.

Wash hands after use.

Pregnancy and lactation:

Can be used during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

None known.

## **7. Adverse events**

Cattle (lactating cows)

None known.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system *{national system details}*.

## **8. Dosage for each species, routes and method of administration**

Intramammary use.

The contents of one syringe should be infused into each affected quarter via the teat canal, immediately after milking, at 12 hour intervals for three consecutive milkings. In cases of infections caused by *Staphylococcus aureus*, a longer course of antibacterial therapy may be required. Therefore overall treatment length must be at the veterinarian's discretion but should be long enough to ensure complete resolution of intramammary infection.



## **9. Advice on correct administration**

Before the infusion is made, the teat end should be cleaned and disinfected.

## **10. Withdrawal periods**

Meat and offal: 7 days.

Milk: 84 hours, i.e. 7 milking times with 2 times a day milking or 11 milking times with 3 times a day milking.

## **11. Special storage precautions**

Keep out of the sight and reach of children.

Do not store above 25 °C.

Store in a dry place.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

## **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

## **14. Marketing authorisation numbers and pack sizes**

Vm 60021/3038

Pack sizes:

Carton containing 3, 12, 24 or 300 intramammary syringes.

Not all pack sizes may be marketed.

## **15. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

**16. Contact details**

Marketing authorisation holder and contact details to report suspected adverse reactions:

Zoetis Belgium S.A.  
2nd Floor, Building 10  
Cherrywood Business Park  
Loughlinstown  
Dublin 18  
D18 T3Y1  
Ireland

Manufacturer responsible for batch release:

Haupt Pharma Latina S.r.l.  
Strada Statale 156 Dei Monti Lepini Km 47600  
Latina  
04100  
Italy

Local representatives and contact details to report suspected adverse reactions:

*To be completed nationally*

*To be completed nationally*

*Gavin Hall*

Approved: 14 January 2025